Focal segmental glomerulosclerosis (FSGS)
Bedside summary
A podocyte-injury pattern (not a single disease) causing focal (some glomeruli) and segmental (part of the tuft) sclerosis. A leading cause of nephrotic syndrome and ESKD, especially in adults and people of African ancestry (APOL1 risk variants). Primary (immune/permeability-factor mediated, abrupt nephrotic syndrome) vs secondary (adaptive hyperfiltration: obesity, reflux, reduced nephron mass, sickle cell; or drug/virus-associated: pamidronate, interferon, anabolic steroids, HIV). Often has haematuria, hypertension and impaired GFR, and is more steroid-resistant than minimal change — distinguishing primary (immunosuppress) from secondary (RAS blockade + treat cause) is central.
Red flags
- Collapsing variant with rapid GFR loss — consider HIV, severe disease; poor prognosis
- Steroid-resistant nephrotic syndrome with progressive CKD
- Thromboembolism/infection complicating nephrotic state
- AKI superimposed (overdiuresis, drug toxicity)
- Mislabelling secondary FSGS as primary and giving futile/harmful immunosuppression
Assessment
Differential diagnosis
- Minimal change disease (younger, fully steroid-responsive, normal GFR/BP)
- Membranous nephropathy, diabetic nephropathy
- Secondary FSGS (obesity/hyperfiltration, reflux nephropathy, reduced nephron mass, sickle cell)
- HIV-associated nephropathy (collapsing FSGS)
- Hypertensive nephrosclerosis
Investigations
- Urine PCR/ACR + microscopy (proteinuria often nephrotic-range; may have haematuria)
- Serum albumin, U&E/creatinine/eGFR, lipids, BP
- HIV serology (collapsing variant), consider parvovirus/other; drug history (bisphosphonates, anabolic steroids, interferon)
- Immunology to exclude mimics (ANA, complement, anti-PLA2R)
- APOL1 context in at-risk ancestry (research/specialist); renal ultrasound (kidney size/scarring)
- Renal biopsy for diagnosis and to judge primary vs secondary (degree of foot-process effacement on EM: diffuse in primary, segmental in secondary)
Management
- Biopsy to confirm and determine primary vs secondary (clinical course + EM foot-process effacement guide this)
- All patients: maximal supportive renoprotection — ACEi/ARB to reduce proteinuria, BP control, SGLT2 inhibitor, statin, sodium restriction, weight management
- Primary FSGS with nephrotic syndrome: immunosuppress with high-dose corticosteroids as first-line induction; calcineurin inhibitor for steroid-resistant/intolerant disease
- Secondary/adaptive FSGS: do NOT immunosuppress — treat the underlying cause (weight loss, stop offending drug, ART for HIV) plus RAS blockade
- Manage nephrotic complications (oedema, VTE risk, infection) as per nephrotic syndrome
- Monitor response (proteinuria reduction) and eGFR; escalate steroid-sparing agents (CNI, MMF, rituximab in selected cases) via nephrology for resistant primary disease
- Plan for CKD trajectory; counsel on recurrence risk post-transplant in primary FSGS
Drugs & doses
Disposition
Complications & pitfalls
- Progression to ESKD (one of the commonest glomerular causes of kidney failure)
- Steroid/immunosuppression toxicity
- Nephrotic complications: VTE, infection, hyperlipidaemia
- Recurrence in renal allograft (primary FSGS) — can be immediate and severe
- Resistant hypertension
Exam pearls
- The pivotal clinical decision is primary vs secondary FSGS: primary = abrupt full nephrotic syndrome with diffuse foot-process effacement on EM -> immunosuppress; secondary/adaptive = slower, sub-nephrotic, segmental effacement -> treat the cause + RAS blockade, do NOT immunosuppress.
- FSGS is more steroid-resistant than minimal change — allow a longer steroid course (up to ~16 weeks) before declaring resistance in primary disease.
- Consider HIV (collapsing FSGS) and APOL1-related risk in patients of African ancestry.
- Primary FSGS can recur in a transplant within hours-days due to a circulating permeability factor — flag for the transplant team.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.